Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
| Industry | Market Weight | YTD Return | |
|---|---|---|---|
| All Industries | 100.00% | 1.90% | |
| Drug Manufacturers - General | 32.83% | -1.94% | |
| Medical Devices | 13.49% | 5.22% | |
| Healthcare Plans | 12.39% | 3.66% | |
| Diagnostics & Research | 11.35% | 4.33% | |
| Biotechnology | 10.73% | -1.36% | |
| Medical Instruments & Supplies | 8.41% | 6.87% | |
| Medical Care Facilities | 2.96% | 4.73% | |
| Drug Manufacturers - Specialty & Generic | 2.72% | 3.51% | |
| Medical Distribution | 2.60% | 5.93% | |
| Health Information Services | 2.34% | 5.91% | |
| Pharmaceutical Retailers | 0.17% | 32.90% | |
Note: Percentage % data on heatmap indicates Day Return
All Industries
--
<= -3
-2
-1
0
1
2
>= 3
Largest Companies in This Sector
View MoreName | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
|---|---|---|---|---|---|---|---|
| | 999.43 | 10.32% | | | | Buy | |
| | 625.10 | 7.42% | | | | Buy | |
| | 175.98 | 5.60% | | | | Buy | |
| | 208.90 | 4.79% | | | | Buy | |
| | 133.43 | 3.92% | | | | Buy | |
| | 657.43 | 3.38% | | | | Buy | |
| | 539.24 | 3.34% | | | | Buy | |
| | 130.24 | 3.11% | | | | Buy | |
| | 288.34 | 2.72% | | | | Buy | |
| | 32.62 | 2.36% | | | | Buy |
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| | 36.396B | 0.09% | | |
| | 18.975B | 0.10% | | |
| | 6.463B | 0.45% | | |
| | 6.369B | 0.35% | | |
| | 4.4B | 0.40% | |
Mutual Fund Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| | 40.511B | 0.30% | | |
| | 40.511B | 0.30% | | |
| | 18.975B | 0.10% | | |
| | 13.014B | 0.80% | | |
| | 13.014B | 0.80% | |
Healthcare Research
View MoreDiscover the Latest Analyst and Technical Research for This Sector
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, MCOs bracing for policy changes; Hong Kong real estate in a good state; Wayfair stock worth building a position in; and Macy's, Akzo Nobel, and Truist Financial.
Analyst Report: Unitedhealth Group Inc
By revenue, UnitedHealth Group is the nation's largest publicly traded managed care company. It operates through two business segments, UnitedHealthcare and Optum. UnitedHealthcare provides healthcare benefits through four membership groups: Employers & Individual, Medicare & Retirement, Community & State, and International. Optum is a health services business that serves payers, care providers, employers, governments, life science companies, and consumers. OptumInsight uses advanced data analytics and technology to help optimize the performance of clients. Optum includes OptumRx, which operates a pharmacy benefit management service (PBM).
RatingPrice TargetMarket Update: BK, PNC, UNH
Stocks are solidly higher at midday on Friday and are on track to have the best week so far in 2025. Good news on inflation this week brought expectations that the Federal Reserve will indeed cut interest rate at some point in 2025 (we believe in the second half) and earnings season is off to a strong start with generally positive results from banks. Meanwhile, there is some progress in one of the global hotspots, as a ceasefire is due to take hold in the conflict between Israel and Hamas.
Analyst Report: Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
RatingPrice Target


















